Cargando…
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
Autores principales: | Matutes, E, Bosanquet, A G, Wade, R, Richards, S M, Else, M, Catovsky, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567236/ https://www.ncbi.nlm.nih.gov/pubmed/22810506 http://dx.doi.org/10.1038/leu.2012.209 |
Ejemplares similares
-
The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
por: Oscier, David, et al.
Publicado: (2016) -
The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
por: Else, Monica, et al.
Publicado: (2015) -
The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial
por: Else, Monica, et al.
Publicado: (2021) -
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial
por: Strefford, JC, et al.
Publicado: (2015) -
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial
por: Blakemore, Stuart J., et al.
Publicado: (2020)